US2021395295A1PendingUtilityA1
Inhibitors of glucocorticoid receptor
Est. expiryDec 23, 2035(~9.4 yrs left)· nominal 20-yr term from priority
Inventors:Daqing SunLawrence R. McgeeXiaohui DuLiusheng ZhuXuelei YanYosup RewJohn EksterowiczJulio C. MedinaHaiying ZhouMinna D. BalbasValeria R. Fantin
C07J 17/00A61K 45/06A61P 43/00C07J 41/0094C07J 1/0096C07J 51/00A61P 15/00A61K 31/567C07J 41/0083A61K 31/473A61K 31/277A61K 31/58C07J 31/006A61P 11/00C07J 21/006C07J 43/003C07J 71/001A61P 5/00C07B 2200/05A61P 35/00A61P 5/44C07J 41/0088A61P 13/08A61K 31/57
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.
Claims
exact text as granted — not AI-modified1 .- 49 . (canceled)
50 . A compound having the structure of Formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof:
wherein
R 1 is —NR 4 R 5 ;
each R 2 is independently —NR 4 R 5 , alkylNR 4 R 5 , halo, —OR 6 , —OH, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, heteroalkyl, heterocyclyl, heterocyclylalkyl, hydroxy alkyl, —C(O)R 6 , —C(O)OR 6 , —C(O)NR 4 R 5 , —OC(O)OR 6 , —OC(O)NR 4 R 5 , —S(O) 2 NR 4 R 5 , —S(O) 2 R 7 , —S(O)R 7 , —SR 7 , —NR 4 S(O) 2 NR 4 R 5 , —CN, —CO 2 H, or —NO 2 ;
R 3 is C 2-10 alkyl, haloalkyl, halo, deuteroalkyl, carbocyclyl, carbocyclylalkyl heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, —Si(R 6 ) 3 , —OR 6 , or —S(O) 2 R 7 ;
R 4 and R 5 are each independently —H, alkyl optionally substituted with —OR 6 , haloalkyl, carbocyclyl, aryl, heterocyclyl, heteroaryl, —S(O) 2 R 7 , —C(O)N(R 10 ) 2 , —C(O)R 6 , or —C(O)OR 6 ;
or R 4 and R 5 attached to the same N atom are taken together with the N atom to which they are attached to form a heterocycle optionally substituted with alkyl optionally substituted with —OH, —OH, —OR 6 , —S(O) 2 R 7 , —C(O)N(R 10 ) 2 , —C(O)R 6 , or —C(O)OR 6 ;
each R 6 is independently alkyl optionally substituted with —OH, haloalkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl;
R 7 is alkyl, haloalkyl, carbocyclyl, heteroalkyl, aryl, aralkyl, heterocyclyl, or heteroaryl;
each R 10 is independently H, alkyl, haloalkyl, carbocyclyl, heteroalkyl, aryl, aralkyl, heterocyclyl, or heteroaryl; and
n is 1, 2, 3, or 4.
51 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein each R 2 is independently —NR 4 R 5 , halo, alkyl, carbocyclyl, alkoxy, or —CN.
52 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein R 4 and R 5 are each independently —H, alkyl, or —S(O) 2 R 7 .
53 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein
R 4 and R 5 attached to the same N atom are taken together with the N atom to which they are attached to form a 4-, 5-, or 6-membered ring heterocycle additionally containing 0-3 heteroatoms selected from the group consisting of —O—, —NH—, —NR 6 , —S—, and —S(O) 2 —; and R 6 is alkyl.
54 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein R 6 is alkyl, carbocyclyl, or fluoroalkyl.
55 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein R 7 is alkyl, carbocyclyl, aryl, aralkyl, or heterocyclyl.
56 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein n is 0.
57 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein n is 1.
58 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein n is 2.
59 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prod rug thereof, wherein the compound of Formula (I) is a compound of Formula (Ib):
60 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (Ic):
61 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (Id):
62 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prod rug thereof, wherein the compound of Formula (I) is a compound of Formula (Ie):
(Formula Ie).
63 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (If):
64 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (Ig):
65 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (Ih):
66 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of Formula (I) is a compound of Formula (Ii):
67 . The compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the compound of formula (I) is a compound of Formula (Ij):
68 . A pharmaceutical composition comprising a compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and at least one pharmaceutically acceptable excipient.
69 . A method for treating cancer in a subject, the method comprising administering a therapeutically effective amount of a compound of claim 50 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to the subject in need thereof, wherein the cancer is triple negative breast cancer, high grade serous ovarian cancer, castration resistant prostate cancer, doubly resistant prostate cancer, or non-small cell lung cancer.
70 . The method of claim 69 , wherein the cancer is triple negative breast cancer, high grade serous ovarian cancer, castration resistant prostate cancer, or doubly resistant prostate cancer.
71 . The method of claim 69 , wherein the cancer is non-small cell lung cancer.
72 . The method of claim 69 , further comprising administering one or more additional therapeutic agents to the subject.
73 . The method of claim 72 , wherein the one or more additional therapeutic agents are androgen receptor signaling inhibitors.
74 . The method of claim 73 , wherein the androgen receptor signaling, inhibitor is 3,3′-diindolylmethane (DIM), abiraterone acetate, ARN-509, bexlosteride, bicalutamide, dutasteride, epristeride, enzalutamide, finasteride, flutamide, izonsteride, ketoconazole, N-butylbenzene-sulfonamide, nilutamide, megestrol, steroidal antiandrogens, turosteride, or any combinations thereof.Join the waitlist — get patent alerts
Track US2021395295A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.